Fig. 2
Cytotoxicity of Anetumab Ravtansine as Measured with Cell Viability. The effects of anetumab ravtansine at 0 nM, 10 nM, 50 nM, and 100 nM on mero-95 cell lines in the presence of no pretreatment (pre-Tx), DMSO control, recombinant MSLN (rMSLN), marimastat (M), TMI-1 (T), and a combination of both protease inhibitors (M + T). At baseline, the combination M + T resulted in decreased cell viability compared to the control (p = 0.0016), rMSLN (p = 0.0453), M (p = 0.012), T (p = 0.014). There was a trend of decreased viability at 10 nM, but this was not statistically significant. At 50 and 100 nM, M + T continued to reduce viability, which was significant at 100 nM. Otherwise, there were no significant differences between the groups at 10, 50, and 100 nM. See Supplemental Table 1 for more detailed results. ARav = anetumab ravtansine. * p ≤ 0.05, ** p ≤ 0.01.
